AHL
GMAB icon

Abel Hall LLC’s Genmab GMAB Stock Holding History

Abel Hall LLC’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,638
Closed -$266K – 878
2025
Q4 		$266K Buy
+8,638
New +$269K 0.06% 394

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Abel Hall LLC's GMAB Position: Q1 2026 in Review

Abel Hall LLC sold out of Genmab (GMAB) in Q1 2026, closing a stake of 8,638 shares — an estimated $266K sold.

Abel Hall LLC first reported a position in GMAB in Q4 2025 and held it in 1 quarter. The position peaked at $266K in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Abel Hall LLC reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Abel Hall LLC sold 8,638 Genmab shares in Q1 2026, an estimated $266K.
  • Abel Hall LLC first reported a position in Genmab in Q4 2025 and held it in 1 quarter.
  • Abel Hall LLC's Genmab position peaked at $266K in Q4 2025.
  • 275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.